Placeholder Banner

BIO Applauds Support for Innovation in Trump Administration Task Force Report

January 9, 2018

The report was presented yesterday to President Donald Trump by Secretary of Agriculture Sonny Perdue during the American Farm Bureau Federation’s Annual Convention in Nashville. 

“Globally, the biotechnology sector is a driver of the ‘fourth industrial revolution,’ and presents an incredible opportunity for American farmers and rural communities to thrive at the forefront of innovation,” the report states.

“BIO applauds the report and agrees with the broad recommendation to leverage U.S. investments in technological innovation, improve access to capital in rural communities, and increase market opportunities,” said BIO’s President & CEO Jim Greenwood.

“As the report states, scientific advancements in biotechnology have produced a thriving and successful industrial sector aimed at addressing our world’s most pressing challenges,” added Greenwood. “Further innovations in genome editing technology will unlock even more promises in agriculture production, animal health and welfare, biofuels and renewable chemical development, and biobased manufacturing.”

Greenwood also welcomed recommendations contained in the report, such as the need for policies that promotes economic growth, innovation, competitiveness and job creation.

“As recommended in the report, BIO supports a more harmonized Coordinated Framework for the regulation of biotechnology, a tax code that encourages investment in the biotech sector, and government-backed communications to further public awareness of biotech products,” Greenwood said. “We also need to integrate a recognition for the importance of science and technology into the appropriate Farm Bill titles.” 

Discover More
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…